235 related articles for article (PubMed ID: 11487448)
41. Treating dyslipidemic patients with lipid-modifying and combination therapies.
Worz CR; Bottorff M
Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
[TBL] [Abstract][Full Text] [Related]
42. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
Davidson MH
Curr Atheroscler Rep; 2003 Sep; 5(5):418-22. PubMed ID: 12911853
[No Abstract] [Full Text] [Related]
43. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
44. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
45. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
[TBL] [Abstract][Full Text] [Related]
46. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
47. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
Ito MK
Ann Pharmacother; 2004 Feb; 38(2):277-85. PubMed ID: 14742767
[TBL] [Abstract][Full Text] [Related]
48. Perspectives on low-density lipoprotein cholesterol goal achievement.
Catapano AL
Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
[TBL] [Abstract][Full Text] [Related]
49. Treating mixed dyslipidemias: why and how.
Ballantyne CM
Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
[TBL] [Abstract][Full Text] [Related]
50. Extended-release niacin for modifying the lipoprotein profile.
Guyton JR
Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
[TBL] [Abstract][Full Text] [Related]
51. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Ayyobi AF; Brunzell JD
Am J Cardiol; 2003 Aug; 92(4A):27J-33J. PubMed ID: 12957324
[TBL] [Abstract][Full Text] [Related]
52. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
53. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
54. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
55. Treatment of hyperlipidemia with combined niacin-statin regimens.
Guyton JR; Capuzzi DM
Am J Cardiol; 1998 Dec; 82(12A):82U-84U; discussion 85-86U. PubMed ID: 9915667
[TBL] [Abstract][Full Text] [Related]
56. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
57. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Schectman G; Hiatt J
Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
[TBL] [Abstract][Full Text] [Related]
58. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Ginsberg HN
Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
[TBL] [Abstract][Full Text] [Related]
59. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
Ryan MJ; Gibson J; Simmons P; Stanek E
Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
